Navigation Links
Advanced Life Sciences Receives Nasdaq Notification
Date:3/7/2008

vide written notification that the Company's securities will be delisted. At that time, the Company may appeal the Staff's determination to delist its common stock.

About Advanced Life Sciences

Advanced Life Sciences is a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, cancer and respiratory diseases. The Company's lead candidate, cethromycin, is a novel once-a-day oral antibiotic in late-stage clinical development for the treatment of respiratory tract infections including CAP. For more information, please visit us on the web at http://www.advancedlifesciences.com.

Forward-Looking Statements

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our management's judgment regarding future events including statements regarding the Company's ability to comply with the minimum bid price requirements under the Nasdaq Marketplace Rules or any appeal associated therewith.

The Company does not undertake any obligations to update any forward-looking statements whether as a result of new information, future events or otherwise. Our actual results could differ materially from those discussed herein due to several factors including the our ability to obtain and maintain regulatory approval and labeling of our product candidates; our plans to develop and commercialize our product candidates; the loss of key scientific or management personnel; the size and growth of potential markets for our product candidates and our ability to serve those markets; regulatory developments in the U.S. and foreign countries; the rate and degree of market acceptance of any future products; the accuracy of our estimates regardi
'/>"/>

SOURCE Advanced Life Sciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
3. Advanced Cell Technology Announces Proposed Financing
4. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
5. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
6. Advanced Life Sciences to Present at 2007 UBS Global Life Sciences Conference
7. CeloNova BioSciences Announces Worlds First Line of Fully Color-Coded Embolic Particles at CIRSE: Embozene(TM) Color-Advanced Microspheres
8. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
9. Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System
10. NIH Announces Advanced Cell Technologys Single Cell Embryo Biopsy Technique as a Means to Derive Embryonic Stem Cells to be Considered for Federal Funding
11. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... September 24 marks ASEA's "Meet ASEA" grand ... manufacturer of the world's first and only redox signaling ... , The Mexico City event features renowned speakers Dr. ... Field Leader Shawn Catmull from Draper, UT. , Dr. ... from the University of Utah and devotes his career ...
(Date:9/17/2014)... Sept. 17, 2014 /PRNewswire/ - Oncothyreon Inc. (NASDAQ: ... offer and sell shares of its Common Stock and ... underwritten public offerings.  The Series A Convertible Preferred Stock ... Stock, provided that conversion will be prohibited if, as ... own more than 4.99% of the Common Stock then ...
(Date:9/17/2014)... 2014 A biodegradable polymer can ... as bacteria, fungi, and algae into smaller units ... inorganic compounds, carbon dioxide, and humus in a ... and improved costs, biodegradable polymers are proving to ... to conventional polymers. Primary factors that are responsible ...
(Date:9/17/2014)... Sept. 17, 2014 Intarcia Therapeutics, Inc. ... from a study of the cost and predictability of ... th Annual Meeting of the European Association for ... today, Christian Frois , Ph.D., of Analysis Group, ... of planned Intarcia-sponsored, retrospective studies to characterize the prevalence ...
Breaking Biology Technology:Announcing the ASEA Mexico Grand Opening Tour Beginning September 18th 2Oncothyreon Announces Proposed Public Offerings 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 2Growing Demand for Eco-Friendly Products Drives the Global Biodegradable Polymers Market, According to New Report by Global Industry Analysts, Inc. 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 2Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 3Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 4Intarcia Reveals New Insights At EASD Meeting Characterizing The Burden Of Poor Control And Non-Adherence To Anti-Diabetic Therapies 5
... Gen-Probe Incorporated (NASDAQ: GPRO ) announced today ... results on Thursday, April 28, 2011 at approximately 4:00 pm ... conference call with management at 4:30 pm ET.   ... be accessed on the investors section of the Company,s web ...
... 14, 2011 /PRNewswire-Asia/ -- Global Pharm Holdings Group, Inc. ... or the "Company"), a Shenzhen-based, leading vertically integrated pharmaceutical ... its subsidiaries in Anhui, Jilin, and Shandong provinces, today ... 31, 2010. Fiscal Year 2010 Highlights ...
... TRIANGLE PARK, N.C., April 14, 2011 Talecris Biotherapeutics Holdings ... quarter earnings release after the market closes on April 27, ... will not be hosting a conference call to discuss its ... Inspiration. Dedication. Innovation. Talecris ...
Cached Biology Technology:Gen-Probe Announces Webcast of First Quarter 2011 Earnings Conference Call 2Global Pharm Holdings Group Announces Fiscal Year 2010 Financial Results 2Global Pharm Holdings Group Announces Fiscal Year 2010 Financial Results 3Global Pharm Holdings Group Announces Fiscal Year 2010 Financial Results 4Global Pharm Holdings Group Announces Fiscal Year 2010 Financial Results 5Global Pharm Holdings Group Announces Fiscal Year 2010 Financial Results 6Global Pharm Holdings Group Announces Fiscal Year 2010 Financial Results 7Global Pharm Holdings Group Announces Fiscal Year 2010 Financial Results 8Global Pharm Holdings Group Announces Fiscal Year 2010 Financial Results 9
(Date:9/16/2014)... Researchers at the Columbia Center for Children,s Environmental Health ... first to demonstrate an association between childhood asthma and ... array of household products. Results appear online in the ... born to mothers exposed during pregnancy to higher levels ... (DnBP) had a 72 percent and 78 percent increase ...
(Date:9/16/2014)... neuroscientists have discovered the "molecular brakes" that time the ... of mice. These "hair cells" translate sound waves into ... are interpreted as sounds. If the arrangement of the ... summary of the research will be published in ... "The proteins Hey1 and Hey2 act as brakes to ...
(Date:9/16/2014)... EUGENE, Ore. -- Each tree species has its own ... researchers and colleagues from other institutions who studied the ... growing on a Panamanian island. , "This study demonstrates ... plant families and with different ecological strategies possess very ... Steven W. Kembel, a former postdoctoral researcher in the ...
Breaking Biology News(10 mins):Phthalates heighten risk for childhood asthma 2Phthalates heighten risk for childhood asthma 3Hey1 and Hey2 ensure inner ear 'hair cells' are made at the right time, in the right place 2Microbiome research shows each tree species has a unique bacterial identity 2
... WEST LAFAYETTE, Ind. - Researchers at Purdue University have ... in spinal cord injuries using nano-spheres that could be ... The synthetic "copolymer micelles" are drug-delivery spheres about 60 ... the diameter of a red blood cell. Researchers ...
... To celebrate the 150th anniversary this month of ... American Institute of Biological Sciences (AIBS) is publishing open ... historic insights into evolution. , The two articles are ... and James T. Costa of Western Carolina University. Padian,s ...
... The National Association of Biology Teachers (NABT) will ... at Naugatuck Valley Community College (NVCC) in Waterbury, ... the NABT annual professional development conference to be ... The Evolution Education Award is cosponsored by the ...
Cached Biology News:Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3Biologists, educators recognize excellence in evolution education 2
...
Anti-Wnt-2 Polyclonal Antibody Description: 100 g purified goat polyclonal antibody. Reacts with human/mouse/rat. Tested in Western blot/IP/IHC. Research Focus: signal transduction Storage...
... custom microplate coating using advanced automated high throughput microplate processing ... We can also accommodate virtually any lot size of the ... , 8 and 12 well ... 384 well microplate, ...
...
Biology Products: